TrialEuropean heart journal2013

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

HPS2-THRIVE Collaborative GroupPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.